Abstracts tagged "insurance and rheumatoid arthritis (RA)"

Abstract Number: 362 • 2017 ACR/ARHP Annual Meeting
Patients’ Experiences and Attitudes about Non-Medical Switching of Biologics: Results from an Online Patient Survey
Amanda Teeple¹, Lorie A. Ellis², Laura Huff³, Chuck Reynolds³, Seth D. Ginsberg⁴, Leah McCormick Howard⁵, Danielle Walls⁶ and Jeffrey R. Curtis⁷, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC, Horsham, PA, ³Benfield | Arthur J. Gallagher & Co., Webster Groves, MO, ⁴Global Healthy Living Foundation, CreakyJoints, Upper Nyack, NY, ⁵National Psoriasis Foundation, Portland, OR, ⁶BDJ Solutions, Melrose, MA, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Health insurance plan designs often have benefits that result in highly prescriptive patient (pt) treatment options that can result in switching of patient’s medications…
Abstract Number: 2831 • 2017 ACR/ARHP Annual Meeting
Real-World Experience with Tofacitinib Versus Adalimumab and Etanercept in Biologic-Naive Patients with RA Previously Treated with Methotrexate: Data from a US Administrative Healthcare Insurance Claims Database
Tim Smith¹, James Harnett¹, David Gruben², Connie Chen¹, Ekta Agarwal¹ and John Woolcott³, ¹Pfizer Inc, New York, NY, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Tofacitinib access has been restricted by many US payers to use after…
Abstract Number: 2123 • 2014 ACR/ARHP Annual Meeting
Significant State-Level Variation in Source of Biologic Drug Coverage Among Beneficiaries with Rheumatoid Arthritis
Chris Tonner¹, Gabriela Schmajuk² and Jinoos Yazdany², ¹3333 California Street, Box 09, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA
Background/Purpose: Biologic drugs can be obtained both through Medicare's Part B medical benefit (physician administered drugs) or Part D pharmacy benefit (self-administered drugs). Coverage for…
Abstract Number: 998 • 2013 ACR/ARHP Annual Meeting
Adequacy Of Drug Coverage and Cost-Sharing For Medicare Beneficiaries With Rheumatoid Arthritis
Jinoos Yazdany¹, R. Adams Dudley², Randi Chen³ and Chien-Wen Tseng⁴, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California San Francisco Philip R. Lee Institute for Health Policy Studies, San Francisco, CA, ³Pacific Health Research and Education Institute, Honolulu, HI, ⁴Dept of Family Medicine and Community Health, University of Hawaii and Pacific Health Research and Education Institute, Honolulu, HI
Background/Purpose : Biologic and non-biologic disease-modifying anti-rheumatic drugs (DMARDs) significantly reduce pain, disability and mortality in rheumatoid arthritis (RA). We evaluated how well RA drugs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].